Alaunos Therapeutics gets Nasdaq delisting notice

Nasdaq notified Alaunos Therapeutics that its securities are subject to delisting for noncompliance with Listing Rule 5550(b)(1) requiring at least $2.5 million in stockholders’ equity. The company plans to request a hearing before the Nasdaq Hearings Panel.